BRIGHT-4 trial: bivalirudin strikes back – Authors' reply
We thank Pierre-Guillaume Piriou and colleagues for their interest in our Article.1
Stay updated with breaking news from Ablative Solutions. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
We thank Pierre-Guillaume Piriou and colleagues for their interest in our Article.1
The SPYRAL HTN-ON MED trial missed its primary endpoint, likely caused in part by imbalances in medication use.
/PRNewswire/ -- The "China Deep Vein Thrombosis Interventions Landscape, Procedure and Technology Trends, Brand Perception, Competitive Intelligence and Future...
The Heat Exchanger Market worth in 2021 was USD 16.32 billion, with a 5.31% CAGR, and it's poised to touch USD 25.91 billion by the year of 2030 according...
AKI is a complex clinical syndrome associated with an increased risk of morbidity and mortality, par